vincerx is a clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer.
Company profile
Ticker
VINC
Exchange
Website
CEO
Andrew Ian McDonald
Employees
Location
Fiscal year end
Industry (SIC)
Former names
LifeSci Acquisition Corp., Vincera Pharma, Inc.
SEC CIK
Corporate docs
Subsidiaries
VNRX Corp. • Vincerx Pharma GmbH • Vincerx Pharma Australia ...
IRS number
833197402
VINC stock data
Latest filings (excl ownership)
8-K
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
25 Apr 24
424B5
Prospectus supplement for primary offering
25 Apr 24
ARS
2023 FY
Annual report to shareholders
10 Apr 24
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
8-K
Other Events
8 Apr 24
8-K
Entry into a Material Definitive Agreement
29 Mar 24
424B5
Prospectus supplement for primary offering
29 Mar 24
8-K
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
29 Mar 24
10-K
2023 FY
Annual report
29 Mar 24
Latest ownership filings
SC 13G/A
GOLDMAN SACHS GROUP INC
9 Apr 24
4
Raquel E. Izumi
8 Mar 24
4
Alexander A. Seelenberger
8 Mar 24
4
Ahmed MD Hamdy
8 Mar 24
4
TOM C THOMAS
8 Mar 24
SC 13G/A
Long Focus Capital Management, LLC
14 Feb 24
SC 13G
BANK OF AMERICA CORP /DE/
13 Feb 24
SC 13G/A
Affinity Asset Advisors, LLC
13 Feb 24
SC 13G/A
GOLDMAN SACHS GROUP INC
5 Feb 24
4
Alexander A. Seelenberger
14 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 15.15 mm | 15.15 mm | 15.15 mm | 15.15 mm | 15.15 mm | 15.15 mm |
Cash burn (monthly) | (no burn) | 2.56 mm | 3.44 mm | 4.37 mm | 2.22 mm | 3.85 mm |
Cash used (since last report) | n/a | 17.66 mm | 23.72 mm | 30.18 mm | 15.28 mm | 26.59 mm |
Cash remaining | n/a | -2.51 mm | -8.58 mm | -15.03 mm | -132.17 k | -11.44 mm |
Runway (months of cash) | n/a | -1.0 | -2.5 | -3.4 | -0.1 | -3.0 |
Institutional ownership, Q2 2023
68.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 36 |
Opened positions | 3 |
Closed positions | 2 |
Increased positions | 5 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 14.86 bn |
Total shares | 14.72 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
GS Goldman Sachs | 2.06 mm | $2.68 bn |
Sage Rhino Capital | 1.69 mm | $2.19 bn |
LifeSci Investments | 1.62 mm | $0.00 |
Affinity Asset Advisors | 1.49 mm | $1.94 bn |
Long Focus Capital Management | 1.10 mm | $1.43 bn |
Tang Capital Partners | 1.03 mm | $0.00 |
Rock Springs Capital Management | 891.72 k | $1.16 bn |
Citadel Advisors | 660.52 k | $858.68 mm |
Schonfeld Strategic Advisors | 601.65 k | $782.14 mm |
Vanguard | 520.27 k | $676.35 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Mar 24 | Tom C Thomas | Stock Option Common Stock | Grant | Acquire A | No | No | 7.38 | 93,750 | 691.88 k | 93,750 |
7 Mar 24 | Ahmed MD Hamdy | Stock Option Common Stock | Grant | Acquire A | No | No | 7.38 | 146,746 | 1.08 mm | 146,746 |
7 Mar 24 | Raquel E. Izumi | Stock Option Common Stock | Grant | Acquire A | No | No | 7.38 | 123,750 | 913.28 k | 123,750 |
7 Mar 24 | Alexander A. Seelenberger | Stock Option Common Stock | Grant | Acquire A | No | No | 7.38 | 93,750 | 691.88 k | 93,750 |
11 Aug 23 | Alexander A. Seelenberger | Common Stock | Buy | Acquire P | No | No | 0.9493 | 10,500 | 9.97 k | 30,280 |
News
Why Alphabet Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
26 Apr 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
26 Apr 24
Vincerx Pharma Sets Pricing For New Public Offering Of Shares And Warrants
26 Apr 24
12 Health Care Stocks Moving In Thursday's After-Market Session
25 Apr 24
Vincerx Pharma Announces Proposed Underwritten Public Offering Of Common Stock And Warrants; No Size Or Amount Disclosed
25 Apr 24
Press releases
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
26 Apr 24
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
25 Apr 24
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
18 Apr 24
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
8 Apr 24
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
29 Mar 24